Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
After receiving the nod from the FDA in July to let third-party developers integrate real-time continuous glucose monitoring data in their devices, Dexcom announced its first partnership is with Garmin. See what Jake Leach, Dexcom’s chief technology officer, said about it here.
Dexcom is making CGM data available through consumer devices starting with Garmin’s smartwatches and bicycle computers.
Better Therapeutics is developing prescription digital therapeutics for behavioral therapy to address the root causes of cardiometabolic disease.
Massachusetts’ Medicaid program will cover reSET and reSET-O prescription digital therapeutics for the treatment of substance abuse disorder and opioid use disorder.
Digital Health Roundup, August/September 2021: Record Digital Health Funding Q1-3 Of $21.3Bn, AAOS Highlights, Regulatory Updates
In this roundup of developments in digital health, we highlight the key news and announcements from August and September.
The French company is promoting its ScanWatch as the first wearable device to receive FDA clearance for both atrial fibrillation detection through medical grade ECG and measuring SpO2 levels from the wrist.
Yes – the US FDA will adjust poor-fitting practices to accommodate digital devices. But the agency is not going to set aside product review, postmarket quality, and other basic requirements, former FDA device center compliance chief Steve Silverman argues in this opinion piece.
Digital therapeutics company MindMaze SA has closed a $125m investment round from AlbaCore Capital Group, one of Europe’s leading specialist investors focusing on the public and private corporate credit markets. CEO Tej Tadi explained what the firm hopes to do with the funds.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.